赖脯胰岛素治疗糖尿病的临床观察  

Clinical study of insulin Lispro in the treatment of diabetes mellitus

作　　者：崔卫玲[1] 廖志红[1] 李延兵[1] 黄知敏[1] 孟栋栋[1] 胡国亮[1] 翁建平[1] 

机构地区：[1]中山大学附属第一医院内分泌科,广州510080

出　　处：《中国实用内科杂志》2005年第11期1007-1009,共3页Chinese Journal of Practical Internal Medicine

摘　　要：目的评价赖脯胰岛素(Lispro)对糖尿病患者的疗效与安全性。方法2003-112004-07对中山大学附属第一医院的40例糖尿病患者用Lispro治疗前后测定血糖、糖化血红蛋白,并记录Lispro用量、低血糖发生率。结果40例患者入选,39例完成观察。治疗12周后,患者的空腹血糖、标准餐后1h血糖、2h血糖的平均值分别下降了1·12mmol/L、2·37mmol/L和1·92mmol/L;GHbA1c平均值下降1·45%;每天所需Lispro剂量与治疗前常规重组人胰岛素相同,低血糖的发生率较前明显减少。结论Lispro在改善糖尿病患者的血糖控制的同时低血糖发生率低。Objective To assess the efficacy and safety of insulin Lispro in type 1 or type 2 diabetic patients. Methods Forty diabetic patients were assigned to receive premeal insulin Lispro plus bedtime Neutral Protamine Hagedorn （NPH） insulin for 12 weeks, The following characters were compared between before and after treatment, including fasting plasma glucose （FPG） , 1 h and 2 h postprandial glucose （after a standardized meal） , glycosylated hemoglobin （CHbAl c） levels, total daily insulin dose and the number of hypoglycemic episodes. Results Thirty - nine subjects fulfilled the study. After 12 weeks of Lispro treatment, the levels of FPG and 1 h and 2 h postprandial glucose were decreased significantly, being 1.12 retool/L, 2.37 mmol/L and 1, 92 mmol/L respectively; GHbAlc was decreased by 1, 45% （from 8.9% to 7, 5% ）. The dose of insulin Lispro was not changed, compared with the dose of regular human insulin at baseline. The incidence of hypoglycemia was decreased from 19. 5 every week at baseline to 9.8 every week with Lispro. Conclusion lnsulin Lispro is an effective agent for good glucose control with fewer hypoglycemic episodes in diabetic patients.

关 键 词：赖脯胰岛素 糖尿病 

分 类 号：R5[医药卫生—内科学]